Glaukos Corp (NYSE:GKOS) has been assigned an average recommendation of “Hold” from the twelve analysts that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $40.29.
GKOS has been the topic of a number of research analyst reports. Cantor Fitzgerald set a $48.00 target price on Glaukos and gave the company a “buy” rating in a research report on Wednesday, December 27th. Stifel Nicolaus reduced their target price on Glaukos from $42.00 to $39.00 and set a “buy” rating on the stock in a research report on Monday, February 26th. Stephens restated a “buy” rating and issued a $36.00 target price on shares of Glaukos in a research report on Thursday, March 1st. William Blair restated an “outperform” rating on shares of Glaukos in a research report on Friday, March 23rd. Finally, Canaccord Genuity reduced their target price on Glaukos from $48.00 to $43.00 and set a “buy” rating on the stock in a research report on Thursday, March 1st.
In other news, Director Jonathan Silverstein sold 464,583 shares of Glaukos stock in a transaction on Friday, March 2nd. The stock was sold at an average price of $32.29, for a total value of $15,001,385.07. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Orbimed Advisors Llc sold 836,500 shares of Glaukos stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $32.02, for a total value of $26,784,730.00. The disclosure for this sale can be found here. Insiders own 16.40% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Janus Henderson Group PLC grew its stake in Glaukos by 7.2% during the 3rd quarter. Janus Henderson Group PLC now owns 3,344,361 shares of the medical instruments supplier’s stock worth $110,364,000 after purchasing an additional 225,105 shares in the last quarter. Bamco Inc. NY grew its stake in Glaukos by 104.6% during the 3rd quarter. Bamco Inc. NY now owns 2,194,059 shares of the medical instruments supplier’s stock worth $72,404,000 after purchasing an additional 1,121,813 shares in the last quarter. William Blair Investment Management LLC grew its stake in Glaukos by 7.5% during the 4th quarter. William Blair Investment Management LLC now owns 1,979,960 shares of the medical instruments supplier’s stock worth $50,786,000 after purchasing an additional 137,969 shares in the last quarter. BlackRock Inc. grew its stake in Glaukos by 6.5% during the 4th quarter. BlackRock Inc. now owns 1,957,114 shares of the medical instruments supplier’s stock worth $50,200,000 after purchasing an additional 119,811 shares in the last quarter. Finally, Peregrine Capital Management LLC grew its stake in Glaukos by 32.6% during the 4th quarter. Peregrine Capital Management LLC now owns 622,144 shares of the medical instruments supplier’s stock worth $15,958,000 after purchasing an additional 152,990 shares in the last quarter.
Glaukos stock traded up $0.19 during trading on Wednesday, reaching $29.70. 320,613 shares of the company were exchanged, compared to its average volume of 597,735. Glaukos has a 52-week low of $23.08 and a 52-week high of $48.89. The company has a market cap of $1,001.93, a price-to-earnings ratio of 192.27 and a beta of 1.05.
Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, February 28th. The medical instruments supplier reported $0.03 EPS for the quarter, beating the Zacks’ consensus estimate of $0.01 by $0.02. Glaukos had a positive return on equity of 4.03% and a negative net margin of 0.06%. The company had revenue of $41.65 million for the quarter, compared to the consensus estimate of $40.83 million. The company’s quarterly revenue was up 25.6% compared to the same quarter last year. equities analysts predict that Glaukos will post -0.38 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this story on another publication, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this story can be viewed at https://www.thelincolnianonline.com/2018/04/19/glaukos-corp-gkos-given-consensus-recommendation-of-hold-by-brokerages.html.
Glaukos Company Profile
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.